Ben joined BBOT in September 2024 and brings more than 25 years of experience in R&D across the entire life cycle of drug development from early- to late-stage and through commercialization with more than 10 molecules approved in more than 20 indications covering various modalities including small molecules, biologics, ADCs, and more. Prior to joining BBOT, Ben was a Venture Partner at Eight Roads Venture, one of Fidelity’s venture capital firms, and acting CEO of AlphaGen, a radiopharmaceutical biotech, incubated by ERVC and F-Prime Capital. Prior to the venture position, Ben served as Chief Medical Officer, solid tumors, at BeiGene from 2019 to 2022, and as Chief Medical Officer at BioAtla from 2017 to 2019. Previously, he was Global Clinical Leader of Immuno-Oncology Clinical Development at AstraZeneca, leading the approval of IMFINZI^® (durvalumab) in urothelial cancer. Ben’s career highlights also include his work on the approval of NINLARO^® (ixazomib) in multiple myeloma at Millennium Pharmaceuticals and the approval of INLYTA^® (axitinib) in renal cancer at Pfizer.

Ben started his career as a Surgical Oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from UCSD.